BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Terzi E, Piscaglia F, Forlani L, Mosconi C, Renzulli M, Bolondi L, Golfieri R; BLOG-Bologna Liver Oncology Group, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer 2014;14:601. [PMID: 25139639 DOI: 10.1186/1471-2407-14-601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Baimas-George M, Watson M, Sulzer J, Salibi P, Murphy KJ, Levi D, Martinie JB, Vrochides D, Baker EH, Ocuin L, Iannitti DA. Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation. Surg Endosc 2021;35:3122-30. [PMID: 32588344 DOI: 10.1007/s00464-020-07747-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Chen Q, Jia Z, Yang Z, Fan W, Shi H. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization–Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center. Cardiovasc Intervent Radiol 2017;40:1748-55. [DOI: 10.1007/s00270-017-1736-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
4 Yagi R, Midorikawa Y, Moriguchi M, Nakayama H, Aramaki O, Yamazaki S, Higaki T, Takayama T. Liver resection for recurrent hepatocellular carcinoma to improve survivability: a proposal of indication criteria. Surgery. 2018;163:1250-1256. [PMID: 29452700 DOI: 10.1016/j.surg.2017.12.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer 2021;10:522-34. [PMID: 34721513 DOI: 10.1159/000516613] [Reference Citation Analysis]
6 Morisco F, Camera S, Guarino M, Tortora R, Cossiga V, Vitiello A, Cordone G, Caporaso N, Di Costanzo GG; Italian Liver Cancer (ITA.LI.CA) group. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. Oncotarget 2018;9:17483-90. [PMID: 29707122 DOI: 10.18632/oncotarget.24756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Rubinstein MM, Kaubisch A, Kinkhabwala M, Reinus J, Liu Q, Chuy JW. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol 2017;8:1051-5. [PMID: 29299366 DOI: 10.21037/jgo.2017.08.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
8 Cui R, Wang XH, Ma C, Liu T, Cheng ZG, Han ZY, Liu FY, Yu XL, Yu J, Liang P. Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis. Cancer Manag Res 2019;11:10695-704. [PMID: 31920380 DOI: 10.2147/CMAR.S213581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Renzulli M, Clemente A, Brocchi S, Milandri M, Lucidi V, Vukotic R, Cappabianca S, Golfieri R. LI-RADS: a great opportunity not to be missed. Eur J Gastroenterol Hepatol 2019;31:283-8. [PMID: 30234643 DOI: 10.1097/MEG.0000000000001269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
10 Ramazani F, van Nostrum CF, Storm G, Kiessling F, Lammers T, Hennink WE, Kok RJ. Locoregional cancer therapy using polymer-based drug depots. Drug Discovery Today 2016;21:640-7. [DOI: 10.1016/j.drudis.2016.02.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
11 Wei Y, Dai F, Yi Y, Ye W, Zhao W. Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas. Oncol Lett 2018;16:5050-8. [PMID: 30250572 DOI: 10.3892/ol.2018.9263] [Reference Citation Analysis]
12 Sutter O, Fihri A, Ourabia-Belkacem R, Sellier N, Diallo A, Seror O. Real-Time 3D Virtual Target Fluoroscopic Display for Challenging Hepatocellular Carcinoma Ablations Using Cone Beam CT. Technol Cancer Res Treat 2018;17:1533033818789634. [PMID: 30099948 DOI: 10.1177/1533033818789634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
13 Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND, Feng M. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122-130. [PMID: 29066120 DOI: 10.1016/j.ijrobp.2017.09.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 13.2] [Reference Citation Analysis]
14 Ko SY, Choe WH. Potential prognostic factors for solitary hepatocellular carcinoma ≤ 5 cm after transarterial chemoembolization. Korean J Intern Med 2019;34:1210-1. [PMID: 31671925 DOI: 10.3904/kjim.2019.344] [Reference Citation Analysis]
15 Renzulli M, Brocchi S, Pettinari I, Biselli M, Clemente A, Corcioni B, Cappabianca S, Gaudiano C, Golfieri R. New MRI series for kidney evaluation: Saving time and money. Br J Radiol 2019;92:20190260. [PMID: 31046410 DOI: 10.1259/bjr.20190260] [Reference Citation Analysis]
16 Davis CI, Gu X, Kiefer RM, Ralle M, Gade TP, Brady DC. Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. Metallomics 2020;12:1995-2008. [PMID: 33146201 DOI: 10.1039/d0mt00156b] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Cardiovasc Intervent Radiol 2021;44:1048-59. [PMID: 33709273 DOI: 10.1007/s00270-021-02805-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lee SW, Lee TY, Cheng YC, Yen CL, Yang SS. The correlation with tumor radiological characteristics and prognosis of patients with early-stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Medicine (Baltimore) 2021;100:e26414. [PMID: 34190159 DOI: 10.1097/MD.0000000000026414] [Reference Citation Analysis]
19 Damm R, Zörkler I, Rogits B, Hass P, Omari J, Powerski M, Kropf S, Mohnike K, Pech M, Ricke J, Seidensticker M. Needle track seeding in hepatocellular carcinoma after local ablation by high-dose-rate brachytherapy: a retrospective study of 588 catheter placements. J Contemp Brachytherapy 2018;10:516-21. [PMID: 30662474 DOI: 10.5114/jcb.2018.80626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jun BG, Kim SG, Kim YD, Cheon GJ, Han KH, Yoo JJ, Kim YS, Jeong SW, Jang JY, Lee SH, Park S, Kim HS. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis. PLoS One 2018;13:e0206381. [PMID: 30379885 DOI: 10.1371/journal.pone.0206381] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
21 Shiba S, Shibuya K, Katoh H, Kaminuma T, Miyazaki M, Kakizaki S, Shirabe K, Ohno T, Nakano T. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. Radiat Oncol 2019;14:137. [PMID: 31375120 DOI: 10.1186/s13014-019-1347-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
22 Wei Y, Yi Y, Tao C, Ye W, Zhao W. Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas. Cancer Manag Res 2019;11:8475-86. [PMID: 31572002 DOI: 10.2147/CMAR.S201744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Sun JY, Yin T, Zhang XY, Lu XJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 2019;234:12116-21. [PMID: 30648254 DOI: 10.1002/jcp.28019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
24 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
25 Mouli SK, Hickey R, Thornburg B, Sato KT, Desai K, Gabr A, Kallini JR, Niemeri H, Kircher S, Mulcahy MF, Benson Iii AB, Gupta R, Salem R, Lewandowski RJ. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Journal of Vascular and Interventional Radiology 2016;27:1279-87. [DOI: 10.1016/j.jvir.2016.01.135] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
26 Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology 2018;68:449-61. [PMID: 29476694 DOI: 10.1002/hep.29855] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 13.5] [Reference Citation Analysis]
27 Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017;101:2071-2078. [PMID: 28353492 DOI: 10.1097/tp.0000000000001752] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 7.6] [Reference Citation Analysis]
28 Adhoute X, Pénaranda G, Raoul J, Pietri O, Bronowicki J, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. European Journal of Gastroenterology & Hepatology 2019;31:1414-23. [DOI: 10.1097/meg.0000000000001420] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]